Sumitomo Pharma announced that it has decided not to proceed with the planned third-party allotment of shares at the Board of Directors meeting on April 8, 2026, and that the 7,695,600 shares scheduled for issuance will not be issued.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-05-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4506-20260522-01.pdf","jir_short_summary":"Sumitomo Pharma announced that it has decided not to proceed with the planned third-party allotment of shares at the Board of Directors meeting on April 8, 2026, and that the 7,695,600 shares scheduled for issuance will not be issued.","jir_summary":"### Results and Background of the Share Issue\nAt the Board of Directors meeting on April 8, 2026, Sumitomo Pharma resolved to execute a public offering and secondary offering of shares, along with the planned third-party allotment of shares. However, notification was received from SMBC Nikko Securities that no applications would be submitted by the application deadline, resulting in the non-implementation of the share issuance. As a result, the initially scheduled issuance of 7,695,600 shares will not occur, potentially impacting the company's capital raising plans.\n\n### Future Outlook and Investor Impact\nThe non-implementation of the share issue may lead to changes in the company's capital procurement plans and financial strategies, but detailed future policies have not been disclosed. Investors should monitor the company's funding plans and financial status closely.","jir_financial_highlights":"Scheduled Number of Shares to be Issued: 7,695,600 shares (Unknown)\nApplication Deadline: May 25, 2026 (Unknown)","jir_category":"","jir_hashtags":"#SumitomoPharma, #IR_CategoryRelated, #JapanStocks","jir_key_figures":"Scheduled Number of Shares to be Issued: 7,695,600 shares (not implemented)\nApplication Deadline: May 25, 2026 (notified)\nPlanned Capital Increase: Unknown","jir_meta_title":"\u3010Sumitomo Pharma\u3011Share Issue Not Implemented\uff5cMay 22, 2026","jir_meta_description":"Sumitomo Pharma announced that it will not proceed with the planned third-party allotment of shares at the Board of Directors on April 8, 2026, and disclosed that the number of issued shares will be 0.","jir_og_title":"Sumitomo Pharma Share Issue Not Implemented\uff5cMay 22, 2026","jir_og_description":"Sumitomo Pharma has decided not to proceed with the share issuance plan, which may impact its funding activities. Please refer to the IR materials for details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-54172","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n